February 9th. (WHERE IS THE EMERGENCY USE AUTHORIZATION??)
[link to www.ox.ac.uk (secure)]
Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests

Inhaled budesonide reduced the relative risk of requiring urgent care or hospitalisation by 90% in the 28-day study period.

Participants allocated the budesonide inhaler also had a quicker resolution of fever, symptoms and fewer persistent symptoms after 28 days.

The study also demonstrated that there was a reduction in persistent symptoms in those who received budesonide. [Prof. Bafadhel]: I am encouraged to see the reduction in persistent symptoms at 14 and 28 days after treatment with budesonide. Persistent symptoms after the initial COVID-19 illness have emerged as a long-term problem. Any intervention which could address this would be a major step forward.'